Related Experiment Videos
Bisphosphonates for controlling pain from metastatic bone disease
1Department of Pharmacy, University of Michigan Hospitals, University Hospital, Ann Arbor 48109-0008, USA.
Summary
Bisphosphonates show promise in managing cancer-induced bone pain by inhibiting osteoclast activity. Pamidronate, particularly intravenous formulations, appears most effective, though further research is needed on optimal use.
Area of Science:
- Oncology
- Pharmacology
- Pain Management
Background:
- Cancer metastasis to bone is a significant cause of pain.
- Pain mechanisms include inflammatory mediators, tumor invasion, periosteal stretching, and fractures.
- Current pain management involves opioids, NSAIDs, surgery, chemotherapy, radiation, and radiopharmaceuticals.
Purpose of the Study:
- To review the rationale and efficacy of bisphosphonates for managing bone pain in cancer patients.
- To evaluate the potential of bisphosphonates in reducing pain or analgesic requirements.
Main Methods:
- Review of existing literature on bisphosphonates for metastatic bone pain.
- Analysis of bisphosphonate mechanisms of action, including binding to hydroxyapatite and osteoclast toxicity.
- Examination of specific bisphosphonates studied: etidronate, pamidronate, clodronate, and alendronate.
Main Results:
- Bisphosphonates demonstrate some benefit in relieving metastatic bone pain.
- Pamidronate, especially the monthly intravenous formulation, shows the most promise.
- Oral bisphosphonate formulations have limited usefulness due to poor bioavailability and side effects.
- Adverse effects include gastrointestinal reactions, renal impairment, anemia, and electrolyte abnormalities.
Conclusions:
- Bisphosphonates can offer some relief from metastatic bone pain.
- Further research is required to determine the optimal bisphosphonate agent, route of administration, and treatment duration.
- The precise role of bisphosphonates in the multimodal management of bone pain needs further elucidation.